EU-309

N/A

Report date: 2025/01/26 19:26:48

Base Information

Drug NameEU-309
Drug Alias Nameanti-EGFRvIII CAR T-cell therapy (Eutilex)EU-309
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEpidermal growth factor receptor variant III antagonists
TargetsEpidermal growth factor receptor variant IIIEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEutilex
China Registration ClassN/A

Develop Information

Active CompaniesEutilex
Inactive CompaniesN/A
Active IndicationsBrain Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A